cisapride has been researched along with Fetal Growth Restriction in 1 studies
Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed)
cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.
| Excerpt | Relevance | Reference |
|---|---|---|
| " No significant correlation was found between birth weight or gestational age and the change in QTc values during Cisapride treatment in the appropriate for gestational age group." | 5.11 | Intrauterine growth retardation is a risk factor for cisapride-induced QT prolongation in preterm infants. ( Capretti, MG; Corvaglia, L; Faldella, G; Lanari, M; Rotatori, R; Salvioli, GP, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Corvaglia, L | 1 |
| Faldella, G | 1 |
| Rotatori, R | 1 |
| Lanari, M | 1 |
| Capretti, MG | 1 |
| Salvioli, GP | 1 |
1 trial available for cisapride and Fetal Growth Restriction
| Article | Year |
|---|---|
Intrauterine growth retardation is a risk factor for cisapride-induced QT prolongation in preterm infants.
Topics: Anti-Ulcer Agents; Birth Weight; Cisapride; Electrocardiography; Female; Fetal Growth Retardation; H | 2004 |